


Exhibit 99.1



Fourth Quarter 2008 Webcast

February 12, 2009

Alcon[®]

Safe Harbor Statement

This presentation, made on February 12, 2009, includes forward-looking statements based on current expectations and Alcon does not undertake the obligation to update the forward-looking information or statements. These expectations could differ materially from actual results and are subject to a number of uncertainties and risks as detailed in the company's form 20-F filed with the SEC on March 18, 2008.

In addition, this presentation may include several financial measures, to assist in better understanding our business, that are not prepared in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures will be reconciled at the end of this presentation or in associated public information filed with the SEC.

Reports noted above are available on our website at www.alcon.com in the "Investors and Media" section. For further information contact the Alcon Investor Relations Department at (817)551-8805.

Business Overview

Cary Rayment
Chairman, President & CEO

Long-term Opportunity

- Attractive market fundamentals
 - Value of vision to individuals and to society
 - Significant unmet medical needs
 - Aging demographics provide long-term foundation for growth
- Strong competitive position
 - Specialized focus in all areas of eye care
 - Geographic and product diversification mitigates risk
 - Global infrastructure to fulfill expanding global demand
 - Financial resources to support long-term investment in R&D and brand development


2008 Highlights

- Strong full-year financial performance
 - 12.4% reported sales growth, 8.3% organic growth*
 - 29.3% increase in diluted EPS
- Market share gains driving growth
 - Glaucoma
 - Allergy
 - IOLs
 - Phaco systems and disposables
- Global product approvals and launches
 - AcrySof® ReSTOR® +3.0
 - AcrySof® Phakic in E.U.
 - CONSTELLATION®
 - AZARGA® in E.U.
 - TRAVATANZ™ in Japan

* Organic growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic growth are provided in slides at the end of this presentation.

Balanced Growth


Organic Growth* by Product Line



* Organic growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic growth are provided in slides at the end of this presentation.

2008 Geographic Sales and Growth

FY 2008 Sales by Geography



* Constant currency sales growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for constant currency are provided in slides at the end of this presentation.

Growing Market Share in Key Categories

	November YTD 2008	FY 2007	Share Growth
TRAVATAN® + TRAVATAN Z®	17.8%	15.9%	+190 bps
DuoTrav™	20.6%	16.6%	+400 bps
Azopt®	54.2%	51.4%	+280 bps
Vigamox® %	8.7%	7.5%	+120 bps
NEVANAC®	1.9%	1.3%	+60 bps
Patanol® + Pataday®	20.7%	18.2%	+250 bps
CIPRODEX® * / Cipro® HC	8.2%	7.7%	+50 bps
Total IOL's	53.0%*	52.6%*	+40 bps
OPTI-FREE® EXPRESS® + RepleniSH®	51.4%*#	49.0%*#	+240 bps
OTC Dry Eye	24.2%*#	23.2%*#	+100 bps

% Moxifloxacin, the active ingredient in **Vigamox®**, is licensed to Alcon by Bayer HealthCare AG. **Cipro HC®** and **CIPRODEX®** are registered trademarks of Bayer AG and licensed to Alcon by Bayer HealthCare AG.

* Reflects full year data.

Reflects U.S. data only.

Source: Global-IMS, Market Scope and US-Nielsen

Alcon®

Evolution of 2008 Growth

	Alcon Group Reported USD Growth				
	Q1	Q2	Q3	Q4	Full Year
International	25.6%	28.9%	23.8%	1.2%	19.1%
United States	5.9%	7.0%	4.1%	2.8%	5.0%
Alcon Group	16.2%	17.9%	14.1%	1.9%	12.4%


	Alcon Group Organic USD Growth*				
	Q1	Q2	Q3	Q4	Full Year
International	10.2%	13.4%	14.0%	9.3%	11.6%
United States	5.9%	6.5%	3.6%	2.6%	4.7%
Alcon Group	8.1%	10.0%	8.9%	6.4%	8.3%

* Organic growth is a non-GAAP measure presented to give investors a better comparison of operations between years. Reconciliations for organic growth are provided in slides at the end of this presentation.

Growing Glaucoma Sales Faster than Competition

Growth as of November 2008 YTD


Alcon achieved #2 global market share position in glaucoma



Source: IMS Nov 08 Monthly for top 30 countries


Global Growth in Cataract Products

Percent Growth in Cataract Products – FY 2008



*Source: Global procedure growth from Market Scope


Advanced Technology IOL Sales Trend



Source: Company Analysis


Disinfectant Market Share Success

U.S. Equiv. Unit Market Share (including Private Label)



Successful U.S. Launch of Systane® ULTRA

Equiv. Unit Share Launch Comparison by 4 Week Period



* Trademarks are property of their respective owners.

Financial Review

Rick Croarkin

Senior Vice President, Finance and Chief Financial Officer

Sales


4th Qtr

(dollars in millions)

+1.9% Reported

+7.1% Constant Currency*

+6.4% Organic Growth*




Full Year

(dollars in millions)

+12.4% Reported

+9.5% Constant Currency*

+8.3% Organic Growth*




* Constant currency sales growth and organic sales growth are non-GAAP measures presented to give investors a better comparison of operations between years. Reconciliations for constant currency sales growth and organic sales growth are provided in slides at the end of this presentation.

Gross Profit

4th Qtr

(dollars in millions)

+8.0%



% of
Sales


74.7%

79.2%

Full Year

(dollars in millions)

+14.8%



% of
Sales

75.0%


76.6%

Operating Profit

4th Qtr

(dollars in millions)

+20.0%



% of
Sales


32.5%

38.3%

Full Year

(dollars in millions)

+17.5%



% of
Sales

33.6%


35.2%

Net Earnings

4th Qtr

(dollars in millions)


+12.5%



Full Year

(dollars in millions)

+29.0%



Investment Performance and Strategy Update

Fourth Quarter and FY 2008 Investment Performance


- Investments losses totaled \$83.3 million in Q4
 - Includes \$32.1 million of impairment charges
- Full-year 2008 losses of \$133.8 million
 - Includes \$36.5 million of impairment charges

Modifications to Investment Strategy

- Eliminating allocation to REITs and hedge funds
 - REITs fully liquidated in January 2009
 - Hedge fund redemptions will occur in stages through Q4 2009
- Resulting portfolio asset allocation of
 - 90.5% cash, 9% fixed income and 0.5% equities

Consistent Dividend Growth


Dividend Historical Payout vs. 2009 Proposal




* Dividend proposal will be put to a shareholder vote on May 5, 2009. Dividends are declared in Swiss francs; 2009 USD amount is an estimate only.

Industry-leading Margins

Operating
Income
Margin
as a % of
Reported Sales



Net
Earnings
Margin
as a % of
Reported Sales



Source: Company financial statements

* TTM as of latest filing

Alcon[®]

2009 Full Year Financial Guidance

- Organic growth in the mid-single digits
- Diluted earnings per share:

U.S. GAAP EPS guidance	\$6.00 - \$6.20	
<i>Restructuring charge</i>	<i>(0.05)</i>	<i>(0.05)</i>
Adjusted EPS guidance	\$6.05 - \$6.25	



Alcon[®]

Non-GAAP Reconciliations

(dollars in millions) FULL YEAR 2008	FY GAAP Growth Rate	Exchange Rate Changes	FY Constant Currency Growth Rate	Acquisition Rate Changes	FY Organic Growth Rate
Global Sales	12.4%	(2.9%)	9.5%	(1.2%)	8.3%
Pharmaceutical	10.7	(2.5)	8.2	0.0	8.2
Surgical	15.3	(3.6)	11.7	(2.5)	9.2
Consumer	8.3	(2.3)	6.0	0.0	6.0
United States	5.0	0.0	5.0	(0.3)	4.7
International	19.1	(5.6)	13.5	(1.9)	11.6
Developed International	18.0	(6.7)	11.3	NA	NA
Emerging Markets	21.5	(3.4)	18.1	NA	NA

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

Non-GAAP Reconciliations

(dollars in millions) Q4 2008	Q4 GAAP Growth Rate	Exchange Rate Changes	Q4 Constant Currency Growth Rate	Acquisition Rate Changes	Q4 Organic Growth Rate
Global Sales	1.9%	5.2%	7.1%	(0.7%)	6.4%
Pharmaceutical	0.0	4.8	4.8	0.0	4.8
Surgical	3.2	5.3	8.5	(1.5)	7.0
Consumer	2.9	5.8	8.7	0.0	8.7
United States	2.8	0.0	2.8	(0.2)	2.6
International	1.2	9.2	10.4	(1.1)	9.3

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

Non-GAAP Reconciliations

(dollars in millions) Q1 2008	Q1 GAAP Growth Rate	Exchange Rate Changes	Q1 Constant Currency Growth Rate	Acquisition Rate Changes	Q1 Organic Growth Rate
Global Sales	16.2%	(6.8%)	9.4%	(1.3%)	8.1%
United States	5.9	0.0	5.9	0.0	5.9
International	25.6	(13.0)	12.6	(2.4)	10.2

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

Non-GAAP Reconciliations

(dollars in millions) Q2 2008	Q2 GAAP Growth Rate	Exchange Rate Changes	Q2 Constant Currency Growth Rate	Acquisition Rate Changes	Q2 Organic Growth Rate
Global Sales	17.9%	(6.7%)	11.2%	(1.2%)	10.0%
United States	7.0	0.0	7.0	(0.5)	6.5
International	28.9	(13.5)	15.4	(2.0)	13.4

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

Non-GAAP Reconciliations

(dollars in millions) Q3 2008	Q3 GAAP Growth Rate	Exchange Rate Changes	Q3 Constant Currency Growth Rate	Acquisition Rate Changes	Q3 Organic Growth Rate
Global Sales	14.1%	(3.8%)	10.3%	(1.4%)	8.9%
United States	4.1	0.0	4.1	(0.5)	3.6
International	23.8	(7.6)	16.2	(2.2)	14.0

Note: Constant currency sales growth rate calculates sales growth without the impact of foreign exchange fluctuations. Organic sales growth rates calculate sales growth without the impact of foreign exchange and acquisition fluctuations. Management believes constant currency sales growth and organic sales growth are important measures of the company's operations because they provide investors with a clearer picture of the core rate of sales growth due to changes in unit volumes and local currency prices and acquisitions. These measures are considered non-GAAP financial measures as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

Non-GAAP Reconciliations

	<u>Net Earnings Millions</u>	<u>Diluted EPS</u>
2007 reported	\$1,586.4	\$ 5.25
2007 refractive impairment	20.8	0.7
2007 adjusted	<u>\$1,607.2</u>	<u>\$ 5.32</u>
2008 reported	\$ 2,046.5	\$ 6.79
2008 tax adjustment*	(235.7)	(0.79)
2008 adjusted	<u>\$ 1,810.8</u>	<u>\$ 6.00</u>
2008 Reported Growth	29.0%	29.3%
2008 Adjusted Growth	12.7%	12.8%

Note: Adjusted net earnings and adjusted growth measure the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.

Non-GAAP Reconciliations

	in Millions FY 2008	Diluted Earnings Per Share FY 2008
2008 Reported Net Earnings	\$ 2,046.5	\$ 6.79
Impact of Refractive Impairment and Tax Credit	235.7	0.79
2008 Adjusted Net Earnings	<u>\$ 1,810.8</u>	<u>\$ 6.00</u>
	in Millions Q4 2008	Effective Tax Rate
2008 Reported Income Taxes	\$ 35.9	1.7%
Impact of Refractive Impairment and Tax Credit	235.7	
2008 Adjusted Income Taxes	<u>\$ 271.6</u>	13.0%

Note: Adjusted net earnings and adjusted effective tax rate measure the results of the company's operations without certain items that pertained only to the period presented. Management believes these measures are an important measure of the company's operations because it provides investors with a clearer picture of the core operations of the company. This measure is considered a non-GAAP financial measure as defined by Regulation G promulgated by the U.S. Securities and Exchange Commission.